Catalyst Pharmaceuticals (CPRX) Gains from Investment Securities (2012 - 2022)
Catalyst Pharmaceuticals (CPRX) posted Gains from Investment Securities of $129000.0 for Q3 2022, up 596.15% on a QoQ basis from -$26000.0 in Q3 2021, and up 596.15% year-over-year from $18530.4 in Q3 2021.
Catalyst Pharmaceuticals (CPRX) Gains from Investment Securities (2012 - 2022) Analysis & Trends
Catalyst Pharmaceuticals' Gains from Investment Securities history runs 11 years deep, the most recent figure standing at $129000.0 for Q3 2022.
- Quarterly Gains from Investment Securities rose 596.15% year-over-year to $129000.0 in Q3 2022, while the trailing twelve-month figure through Dec 2022 was $111000.0 (changed N/A YoY) and the FY2022 annual result came in at $762000.0, changed N/A from the prior year.
- Gains from Investment Securities was $129000.0 for Q3 2022 at Catalyst Pharmaceuticals, up from -$26000.0 in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $129000.0 in Q3 2022 and bottomed at -$85000.0 in Q2 2020.
- A 5-year average of $4145.8 and a median of -$3665.0 in 2019 frame the typical range for Gains from Investment Securities.
- Annual changes were most pronounced in 2021 — Gains from Investment Securities sank 420.0% — and 2022, when it jumped 596.15%.
- Catalyst Pharmaceuticals' Gains from Investment Securities stood at $25700.0 in 2018, then sank by 138.61% to -$9923.0 in 2019, then surged by 481.21% to $37827.0 in 2020, then plunged by 168.73% to -$26000.0 in 2021, then soared by 596.15% to $129000.0 in 2022.
- Business Quant data shows CPRX's Gains from Investment Securities at $129000.0 in Q3 2022, -$26000.0 in Q3 2021, and $8000.0 in Q2 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Catalyst Pharmaceuticals | 3.85 Bn | 3.09 Bn | 134.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 129,000.00 |
| Sep 30, 2022 | 129,000.00 |
| Sep 30, 2021 | -26,000.00 |
| Sep 30, 2021 | -26,000.00 |
| Jun 30, 2021 | 8,000.00 |
| Jun 30, 2021 | 8,000.00 |
| Mar 31, 2021 | -76,000.00 |
| Mar 31, 2021 | -76,000.00 |
| Dec 31, 2020 | 37,827.00 |
| Dec 31, 2020 | 37,827.00 |
| Sep 30, 2020 | -5,000.00 |
| Sep 30, 2020 | -5,000.00 |
| Jun 30, 2020 | -85,000.00 |
| Jun 30, 2020 | -85,000.00 |
| Mar 31, 2020 | 74,000.00 |
| Mar 31, 2020 | 74,000.00 |
| Dec 31, 2019 | -9,923.00 |
| Dec 31, 2019 | -9,923.00 |
| Sep 30, 2019 | -2,330.00 |
| Sep 30, 2019 | -2,330.00 |